On the afternoon of December 10, 2015, the year-end meeting on pancreatic cancer in Shanghai hosted by Eli Lilly and Company was successfully held. The meeting invited renowned doctors in Shanghai to discuss the current status and trends of pancreatic cancer diagnosis and treatment, exchange multidisciplinary and comprehensive diagnosis and treatment models, and promote multidisciplinary collaboration to fight against the “king of cancers” together. Pancreatic cancer is known as the “king of cancers” and about 90% of them are pancreatic ductal adenocarcinoma (PDAC), which is difficult to be diagnosed at an early stage, highly invasive and prone to tumor cell drug resistance. Therefore, despite the great progress in the treatment of pancreatic cancer in recent years, the 5-year survival rate of pancreatic ductal adenocarcinoma is still less than 5%. A more effective treatment for pancreatic cancer is a hot topic of research for many researchers. As a special guest, Prof. Yu Xian-F of the Department of Pancreatic Surgery, Fudan University Pancreatic Cancer Institute/Fudan University Cancer Hospital gave a keynote speech on the reflection and exploration of individualized treatment of pancreatic cancer and participated in the discussion of standardized treatment of pancreatic cancer. Prof. Yu XianF made an insightful summary of the current individualized treatment of pancreatic cancer. He suggested that population screening should be performed by using molecular biology, and pointed out that not all patients with intermediate and advanced pancreatic cancer have little hope, and that neoadjuvant therapy has the same chance of surgery as long as it is properly screened, emphasizing the necessity of population screening and subgroup analysis. At the same time, Prof. Yu Xian-F called for the joint efforts of medical and surgical departments to fight against the king of cancer, and multidisciplinary MDT individualized treatment will be the new trend of pancreatic tumor treatment in the future. In the discussion session, the experts in the audience had a heated discussion on the standardized treatment of pancreatic cancer, and they agreed that the perspective of improving the efficacy of pancreatic cancer should not be limited to surgery. Pre-operative testing of each patient’s unique biological characteristics and molecular typing, as well as pre-operative evaluation and prediction of the patient’s subsequent outcome, will allow the identification of different subtypes of pancreatic cancer patients and provide them with individualized treatment plans.